| Literature DB >> 28971826 |
Tatiana Vidaurre1, Carlos Santos2, Henry Gómez2, Gustavo Sarria2, Edgar Amorin2, Marga López2, Roxana Regalado2, Javier Manrique2, Duniska Tarco3, Carlos Ayestas4, Mónica Calderón2, Luis Mas2, Silvia Neciosup2, Miriam Salazar2, Juan Carlos Chávez2, Milward Ubillus2, Abel Limache2, José Carlos Ubillus2, Jeannie Navarro2, Kavita Sarwal5, Simon Sutcliffe5, Alfonso Gutiérrez-Aguado6, Marianela Silva7, Amalia Mena8, María Eugenia Guillén2, Carlos Castañeda2, Julio Abugattas2.
Abstract
Following the implementation of the National Cancer Prevention and Control Results-based Budget Programme (PpR Cancer-024) in 2011, the Peruvian Government approved the Plan Esperanza-a population-based national cancer control plan-in 2012. Legislation that ensured full government-supported funding for people who were otherwise unable to access or afford care and treatment accompanied the Plan. In 2013, the Ministry of Health requested an integrated mission of the Programme of Action for Cancer Therapy (imPACT) report to strengthen cancer control in Peru. The imPACT Review, which was executed in 2014, assessed Peru's achievements in cancer control, and areas for improvement, including cancer control planning, further development of population-based cancer registration, increased prevention, early diagnosis, treatment and palliative care, and the engagement and participation of civil society in the health-care system. This Series paper gives a brief history of the development of the Plan Esperanza, describes the innovative funding model that supports it, and summarises how funds are disseminated on the basis of disease, geography, and demographics. An overview of the imPACT Review, and the government's response in the context of the Plan Esperanza, is provided. The development and execution of the Plan Esperanza and the execution of and response to the imPACT Review demonstrates the Peruvian Government's commitment to fighting cancer across the country, including in remote and urban areas.Entities:
Mesh:
Year: 2017 PMID: 28971826 DOI: 10.1016/S1470-2045(17)30598-3
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316